Controlled Release Drug Delivery Market Upcoming Trends, Strategies Development and Forecast 2024 - 2032

The global Controlled Release Drug Delivery Market was valued at USD 49.23 billion in 2022 and is expected to grow at a rapid compound annual growth rate (CAGR) of 10.1% over the forecast period. Key drivers of this growth include rising investments in research and development (R&D), advancements in drug delivery technology, and increasing prevalence of chronic diseases.

Key Market Drivers

One of the most significant advancements propelling the market is the development of nanoparticle drug delivery systems. These nanoparticles are designed to target specific tissues or cells, providing controlled and localized drug release, which minimizes side effects and improves patient outcomes. This has led to significant improvements in the efficiency and quality of treatments.

You Can Download Free Sample PDF Copy Of This Report @ https://www.emergenresearch.com/request-sample/2845

The rising prevalence of chronic diseases such as heart disease, cancer, diabetes, and stroke is also driving market growth. According to the World Health Organization (WHO), chronic diseases are responsible for 71% of global deaths, making long-term and stable drug delivery systems increasingly important. For example, controlled-release insulin is transforming diabetes management by offering better blood sugar control.

Additionally, advancements in designing drug delivery systems that target diseased cells or tissues more effectively have opened new avenues for personalized medicine. These systems, such as nanoparticles that target cancer cells, are helping to reduce systemic exposure and improve treatment effectiveness.

Technological advancements, particularly the integration of Artificial Intelligence (AI) and Machine Learning (ML), are further enhancing drug delivery systems. A notable development is Evonik's launch of RESOMER, a high-precision excipient platform for injectable drug delivery, which offers greater control over drug release.

Market Challenges

Despite the promising growth, the market faces challenges due to stringent regulations and potential side effects associated with controlled release drugs. The complex nature of these systems requires extensive preclinical and clinical trials to ensure safety and efficacy, extending development timelines and increasing costs. Moreover, differing regulations across countries add to the complexity of bringing these drugs to market, further delaying entry and increasing expenses.

Technology Insights

The controlled release drug delivery market is segmented into various technologies, including Wurster technique, coacervation, microencapsulation, and targeted delivery, among others. The targeted delivery segment holds the largest market share, as it offers precise delivery to diseased cells, maximizing the drug's impact while minimizing side effects. This technology is particularly beneficial for diseases like cancer, where traditional drug delivery methods may fall short.

Microencapsulation is another rapidly growing segment. This technology allows for the encapsulation of a wide variety of drugs, enhancing their stability and protecting them from degradation. It also helps in masking unpleasant tastes and odors, making it applicable across pharmaceuticals, nutraceuticals, and cosmetics.

Mechanism Insights

Based on the mechanism of drug delivery, the market is divided into polymer-based systems, feedback-regulated drug delivery systems (FRDDS), and chemically activated systems. The FRDDS segment is expected to dominate the market due to its advanced capability to monitor real-time physiological responses, such as blood glucose levels, and adjust drug release accordingly. These systems optimize treatment by maintaining ideal drug levels and minimizing unnecessary exposure.

Chemically activated systems are also expected to grow steadily, offering the advantage of triggering drug release in response to environmental cues such as pH changes or enzyme activity. This precision in drug release helps reduce off-target effects and improves the overall effectiveness of treatments.

Application Insights

Oral controlled drug delivery remains the most dominant application segment in the market. Patients prefer oral medications for their ease of use, non-invasive nature, and convenience. Oral controlled-release systems are used to treat a variety of chronic conditions, such as diabetes, hypertension, and cardiovascular diseases, by maintaining consistent drug levels in the bloodstream over an extended period.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/controlled-release-drug-delivery-market

Injectable drug delivery systems are projected to experience the fastest growth rate during the forecast period. Injectable systems, especially those designed for long-acting treatments, are particularly effective in targeting specific tissues and are beneficial for treating localized diseases, gene therapies, and delivering biologics. These systems offer more control over drug release, reducing the need for frequent oral medications and improving patient adherence.

Controlled Release Drug Delivery Top Companies and Competitive Landscape

The global CRDD market is fairly fragmented with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective CRDD solutions.

Some major players included in the global CRDD report is:

Merck & Co., Inc.
Alkermes
Johnson & Johnson Private Limited
Coating Place, Inc.
Corium, LLC
Pfizer Inc.
Assertio Holdings, Inc.
GSK plc
Novartis AG
Biogen

Controlled Release Drug Delivery Latest Industry Updates

On 4 January 2023, Biogen and Alcyone Therapeutics announced its partnership to develop a device for delivering gene-silencing drugs (ASO) to treat neurological disorders. Alcyone's ThecaFlex DRx is an implantable device that allows ASOs to bypass traditional injections and directly reach the spinal cord through a subcutaneous port. This offers a less invasive and potentially more reliable way to deliver ASOs compared to repeated injections. This collaboration changes the way for more effective and patient-friendly treatment options for neurological diseases.

On 18 May 2022, DelSiTech and Anticancer Bioscience announced its partnership to develop long-lasting, controlled-release cancer treatments using DelSiTech's silica-based technology. Many promising cancer therapies struggle with limited effectiveness due to issues such as poor solubility, side effects, or instability. This collaboration aims to offers longer intervals between treatments, improving convenience and potentially reducing side effects.
Controlled Release Drug Delivery Market Segmentation Analysis

For the purpose of this report, Emergen Research has segmented the global RDD market on the basis of technology, application, mechanism and region:

Technology Outlook (Revenue, USD Billion; 2019-2032)

Wurster Technique
Coacervation
Micro Encapsulation
Implant
Transdermal
Targeted Delivery
Others

Mechanism Outlook (Revenue, USD Billion; 2019-2032)

Polymer based System
Micro Reservoir Partition Controlled Drug Delivery System
Feedback Regulated Drug Delivery System
Activation Modulated Drug Delivery System
Osmotic Pressure Activated
Hydrodynamic Pressure Activated
Vapor pressure Activated
Mechanically Activated
Magnetically Activated
Chemically Activated
potential of Hydrogen (pH)
Hydrolysis
Enzyme Activated

Application outlook (Revenue, USD Billion; 2019-2032)

Oral Controlled Drug Delivery
Injectable
Transdermal and Ocular Patches
Infusion Pump
Drug Eluting Stents
Metered Dose Inhaler

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2845

Regional Outlook (Revenue, USD Billion; 2019-2032)

North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Benelux
Russia
Rest of Europe
Asia Pacific
China
Japan
South Korea
India
ASEAN Countries
Oceania
Rest of APAC
Latin America
Brazil
Mexico
Rest of LATAM
Middle East & Africa
GCC Countries
Israel
Turkey
South Africa
Rest of Middle East & Africa

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.